Quality Control Order for Polyethylene Material for Moulding and Extrusion Amendment.

## Report on the Polyethylene Material for Moulding and Extrusion Quality Control Amendment Order, 2025 **1. Executive Summary:** This report analyzes the "Polyethylene Material for Moulding and Extrusion Quality Control Amendment Order, 2025," which amends the 2022 Order of the same name. The key change involves the omission of a previously specified item (c) and the insertion of a new item (h) covering high-density polyethylene for pharmaceutical moulding EP/USP grade (CAS No. 25087347) used in the manufacturing of disposable hypodermic syringes and IV catheters. This amendment likely aims to ensure the quality and safety of polyethylene materials used in specific medical applications. The report details these changes, their rationale (as inferred from the text), and potential impact on stakeholders within the chemical and pharmaceutical industries. **2. Introduction:** This report aims to provide a comprehensive overview of the "Polyethylene Material for Moulding and Extrusion Quality Control Amendment Order, 2025," based solely on the provided text. It analyzes the changes introduced by this amendment, its potential implications, and its impact on relevant stakeholders. **3. Policy Overview:** This Order is an *amendment* to the "Polyethylene Material for Moulding and Extrusion Quality Control Order, 2022." The core objective, inferred from the amendment, is to ensure the quality control of polyethylene materials, particularly those used in specific medical applications, such as disposable hypodermic syringes and IV catheters. This suggests a broader objective of maintaining public health and safety by regulating the quality of materials used in medical devices. **4. Background and Rationale:** This amendment appears to address a specific need for quality control regarding high-density polyethylene used in manufacturing disposable hypodermic syringes and IV catheters. The insertion of item (h), specifying the CAS number (25087347) and intended applications (pharmaceutical moulding of syringes and catheters), suggests that this specific type of polyethylene material was either previously unregulated, or the existing regulations were deemed insufficient. The amendment ensures that this specific type of polyethylene material meets the required quality standards, likely driven by concerns over patient safety and the potential for material defects in critical medical devices. The removal of item (c) suggests that the material covered by that item is no longer considered relevant, or perhaps covered by another regulatory action. **5. Key Provisions / Changes:** This amendment introduces the following changes to the "Polyethylene Material for Moulding and Extrusion Quality Control Order, 2022": * **Omission:** Item 'c' and all related entries are omitted from paragraph 1, subparagraph 3, in the proviso. The text does not specify what item 'c' was, therefore it is not possible to comment on the impact of its removal. * **Insertion:** A new item 'h' is inserted after item 'g' within paragraph 1, subparagraph 3, in the proviso. This new item specifies: * **Material:** High-density polyethylene for pharmaceutical moulding EP/USP grade. * **CAS No:** 25087347 * **Application:** Manufacturing of Disposable Hypodermic Syringes plungers and IV Catheter-cannula. The effect of this change is to explicitly include this specific grade and application of high-density polyethylene within the scope of the Quality Control Order. This means that manufacturers using this material for these specific medical devices will now be subject to the quality control requirements outlined in the original 2022 Order. **6. Target Audience and Stakeholders:** The primary target audience includes: * Manufacturers of disposable hypodermic syringes and IV catheters using high-density polyethylene for pharmaceutical moulding EP/USP grade (CAS No. 25087347). * Suppliers of high-density polyethylene for pharmaceutical moulding EP/USP grade (CAS No. 25087347). * The Department of Chemicals and Petrochemicals, responsible for overseeing and enforcing the Quality Control Order. * The Bureau of Indian Standards, consulted in the creation of this amendment, and likely responsible for setting and maintaining the standards. **7. Implementation Aspects (Inferred):** * **Responsible Agency:** The Department of Chemicals and Petrochemicals, as indicated by the order issued under its authority and signed by a Joint Secretary. * **Timelines:** The amendment comes into force on the date of its publication in the Official Gazette (June 12, 2025). This suggests immediate applicability. * Manufacturers using high-density polyethylene for pharmaceutical moulding EP/USP grade (CAS No. 25087347) in disposable hypodermic syringes and IV catheters must now comply with the Bureau of Indian Standards Act, 2016 and the requirements of the original "Polyethylene Material for Moulding and Extrusion Quality Control Order, 2022." **8. Expected Outcomes / Impact of Changes:** The likely intended outcomes of this amendment are: * Improved quality control and safety of disposable hypodermic syringes and IV catheters manufactured using high-density polyethylene for pharmaceutical moulding EP/USP grade (CAS No. 25087347). * Reduced risk of material-related defects in these critical medical devices. * Increased confidence in the safety and reliability of these medical devices among healthcare professionals and patients. * Potentially increased compliance costs for manufacturers who were not previously adhering to the standards now required for this specific type of polyethylene in these specific medical applications. **9. Conclusion:** The "Polyethylene Material for Moulding and Extrusion Quality Control Amendment Order, 2025" is a targeted adjustment to existing regulations that brings the manufacturing of disposable hypodermic syringes and IV catheters using a specific grade of high-density polyethylene under stricter quality control. This amendment underscores the government's commitment to ensuring the safety and reliability of medical devices, highlighting the significance of material quality in critical healthcare applications. Compliance with this amendment is essential for manufacturers to maintain the integrity of their products and contribute to improved patient safety.

Key Entities Referenced